Galera Therapeutics, Inc. is a private clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. Located in the Greater Philadelphia area on the Route 202 High-Tech Corridor, Galera lead technology comprises a portfolio of small molecule superoxide dismutase mimetics that have broad therapeutic applicability. Superoxide, a product of normal cellular oxygen metabolism and certain environmental stresses, is harmful to DNA, RNA, proteins and lipids. This highly reactive molecule is normally managed by one of three superoxide dismutases (SOD1, 2 and 3), but the SOD enzymes are deficient or can be overwhelmed in certain disease ...
Galera Therapeutics, Inc. is a private clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. Located in the Greater Philadelphia area on the Route 202 High-Tech Corridor, Galera lead technology comprises a portfolio of small molecule superoxide dismutase mimetics that have broad therapeutic applicability. Superoxide, a product of normal cellular oxygen metabolism and certain environmental stresses, is harmful to DNA, RNA, proteins and lipids. This highly reactive molecule is normally managed by one of three superoxide dismutases (SOD1, 2 and 3), but the SOD enzymes are deficient or can be overwhelmed in certain disease states. Galera small molecule dismutase mimetics closely mimic the activity of the human superoxide dismutase enzymes and overcome this deficiency. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is initially focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer.
-
Number of Employees:
100-250
-
Annual Revenue:
$0-1 Million